INmune Bio, Inc. - חוב לטווח קצר של החברה INMB

INmune Bio, Inc. (INMB) maintains a minimal environmental footprint due to the outsourcing of its production. The volume of short-term debt demonstrates current financial stability, where 0.00 describes the current status of the metric. The company is implementing advanced immune activation methods for the therapy of cancer and dementia. The proprietary XPro molecule creates a significant competitive advantage by selectively suppressing neuroinflammation in Alzheimer's disease.

The assessment of INmune Bio, Inc. (INMB) financial resilience to market shocks depends on liability management, as the development of cancer immunotherapy and Alzheimer's disease requires a constant influx of grants and investments. An analysis of the company's short-term credits and loans allows for tracking the cost of borrowed capital with maturities of up to one year, which helps investors assess liquidity risk between quarterly SEC reports.